OS Therapies to Participate in Fall 2025 Conferences and Events

• Daytime Emmy Awards participation - 2 nomination for 'Shelter Me: Cancer Pioneers' Comparative Oncology documentary that features clinicians, veterinarians and human & canine patients who participated in OST-HER2 clinical trials

New York, New York--(Newsfile Corp. - October 7, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced its participation in upcoming October 2025 conferences and events.

Cell and Gene Meeting on the Mesa
What: Partnering and one-on-one meetings
When: October 6-8, 2025
Where: Arizona Biltmore, Phoenix, AZ
Who: Paul Romness, Chairman & CEO
How: OS Therapies is now a member of the Alliance for Regenerative Medicine

Roth Annual Healthcare Opportunities Conference
What: Meeting participation and one-on-one meetings
When: October 9, 2025
Where: Metropolitan Club, New York City, NY
Who: Gerald Commissiong, Chief Business Officer

FDA/The Osteosarcoma Institute (OSI) Workshop: Advancing Osteosarcoma Drug Development - Connecting Research and Regulatory Pathways for Improved Outcomes
What: Meeting participation and availability for sideline discussions
When: October 10, 2025
Where: Lincoln Square, Washington, DC
Who: OS Therapies Management & Regulatory Team

BIOFuture 2025
What: Spotlight Panel and one-on-one meetings
When: October 13-15, 2025
Where: Cure, New York City, NY
Who: Gerald Commissiong, Chief Business Officer

52nd Daytime Emmy Awards
Shelter Me: Cancer Pioneers - Nominated for 2 Emmy's trailer here movie here
What: Main awards presentation and select investor meetings
When: October 17, 2025
Where: Pasadena Civic Auditorium, Pasadena, CA
Who: Paul Romness, Chairman & CEO; Gerald Commissiong, Chief Business Officer; Nicola J. Mason, BVetMed, PhD, DACVIM, FRCVS, Veterinarian Advisor; and Serena Subada, Patient Advocate

Maxim Growth Summit: Maxim Group Healthcare Conference
What: Corporate presentation and one-on-one meetings
When: October 22, 2025
Where: Hard Rock Hotel, New York City, NY
Who: Paul Romness, Chairman & CEO; and Gerald Commissiong, Chief Business Officer

BIO - Europe
What: Partnering and one-on-one meetings
When: November 3-5, 2025
Where: Vienna, Austria
Who: Paul Romness, Chairman & CEO

About OS Therapies

OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and Fast-Track and Orphan Drug designations from the U.S. FDA and European Medicines Agency. The Company reported positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma, demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a Biologics Licensing Application (BLA) to the U.S. FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma.

In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the U.S. FDA and other risks and uncertainties described in "Risk Factors" in the Company's most recent Annual Report on Form 10-K, most recent Quarterly Report on Form 10-Q and other subsequent documents the Company files with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/269474